OCUL: AXPAXLI advances toward 2027 launch with robust clinical data, FDA alignment, and strong commercial plans
The session highlighted progress toward a 2027 launch for AXPAXLI, with a planned NDA submission in Q4 and strong FDA alignment. SOL-1 data showed clear superiority over EYLEA, and commercial readiness is high. Expansion into diabetic retinopathy offers significant growth potential.Based on Ocular…